Upper GI: Pancreatic adjuvant chemotherapy (PRODIGE-24)
Free question published 02 November 2026
A 61-year-old woman has undergone an R0 pancreaticoduodenectomy for a pT3N1 pancreatic ductal adenocarcinoma. She has recovered well, WHO performance status 0, with good organ function and no significant neuropathy. The MDT recommends adjuvant chemotherapy. Which adjuvant regimen offers the greatest overall survival benefit in a fit patient?
- AGemcitabine monotherapy
- BGemcitabine plus capecitabine
- CCapecitabine monotherapy
- DAdjuvant chemoradiotherapy with 5-fluorouracil
- EModified FOLFIRINOX
Why E is correct
The PRODIGE-24/CCTG PA.6 trial showed that adjuvant modified FOLFIRINOX improved median overall survival to 54.4 versus 35.0 months with gemcitabine (HR 0.64; p=0.003) after resection of pancreatic ductal adenocarcinoma. For a fit patient (good performance status, no significant neuropathy) it is the preferred adjuvant regimen, albeit with greater toxicity.
And why the others are not
- AGemcitabine was the comparator arm and was inferior to modified FOLFIRINOX for overall survival.
- BGemcitabine plus capecitabine (ESPAC-4) is a reasonable option for less fit patients, but modified FOLFIRINOX outperformed gemcitabine-based therapy in PRODIGE-24.
- CCapecitabine monotherapy is not the PRODIGE-24 regimen; gemcitabine-capecitabine (ESPAC-4) is an alternative but FOLFIRINOX gave superior survival in fit patients.
- DAdjuvant chemoradiotherapy is not the standard adjuvant approach for resected pancreatic cancer in the UK; systemic chemotherapy is preferred.
Source PRODIGE-24/CCTG PA.6 - Modified FOLFIRINOX versus gemcitabine as adjuvant therapy for resected pancreatic cancer — Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406.
More free upper gi questions
- Upper GI: Gastric HER2-positive metastatic disease (ToGA) · 22 October 2026
- Upper GI: HCC - BCLC stage B intermediate disease · 13 November 2026
- Upper GI: Definitive chemoRT for oesophageal SCC - dose and concurrent chemotherapy · 11 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing